FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013994792> ?p ?o ?g. }

• W2013994792 endingPage "e83" @default.
• W2013994792 startingPage "e83" @default.
• W2013994792 abstract "Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients. Nevertheless, drug resistance is the major cause of treatment failure in children with ALL. The drug methotrexate (MTX), which is widely used to treat many human cancers, is used in essentially all treatment protocols worldwide for newly diagnosed ALL. Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells. This lack of knowledge is due in part to the fact that existing in vitro methods are not sufficiently reliable to permit assessment of MTX resistance in primary ALL cells. Therefore, we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX.We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial up-front in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX. To identify genomic determinants of these effects, we performed a genome-wide assessment of gene expression in primary ALL cells from 161 of these newly diagnosed children (1-18 y). We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX. This finding was validated in an independent cohort of children with ALL. Furthermore, this measure of initial MTX in vivo response and the associated gene expression pattern were predictive of long-term disease-free survival (p < 0.001, p = 0.02).Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D)." @default.
• W2013994792 created "2016-06-24" @default.
• W2013994792 creator A5000373034 @default.
• W2013994792 creator A5006129290 @default.
• W2013994792 creator A5009866488 @default.
• W2013994792 creator A5018363328 @default.
• W2013994792 creator A5020088480 @default.
• W2013994792 creator A5022483928 @default.
• W2013994792 creator A5034189317 @default.
• W2013994792 creator A5035759509 @default.
• W2013994792 creator A5039997334 @default.
• W2013994792 creator A5049579176 @default.
• W2013994792 creator A5067594062 @default.
• W2013994792 creator A5077339582 @default.
• W2013994792 date "2008-04-15" @default.
• W2013994792 modified "2023-10-17" @default.
• W2013994792 title "In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile" @default.
• W2013994792 cites W1589281120 @default.
• W2013994792 cites W1964895626 @default.
• W2013994792 cites W1971336136 @default.
• W2013994792 cites W1979189074 @default.
• W2013994792 cites W1988377311 @default.
• W2013994792 cites W1988741525 @default.
• W2013994792 cites W2016833582 @default.
• W2013994792 cites W2029441111 @default.
• W2013994792 cites W2038981426 @default.
• W2013994792 cites W2039677781 @default.
• W2013994792 cites W2046065201 @default.
• W2013994792 cites W2057650407 @default.
• W2013994792 cites W2058471639 @default.
• W2013994792 cites W2064613430 @default.
• W2013994792 cites W2075437346 @default.
• W2013994792 cites W2075746486 @default.
• W2013994792 cites W2078491157 @default.
• W2013994792 cites W2083020021 @default.
• W2013994792 cites W2101259585 @default.
• W2013994792 cites W2109363337 @default.
• W2013994792 cites W2118069309 @default.
• W2013994792 cites W2126142122 @default.
• W2013994792 cites W2126838987 @default.
• W2013994792 cites W2132164717 @default.
• W2013994792 cites W2134190122 @default.
• W2013994792 cites W2137476312 @default.
• W2013994792 cites W2138218344 @default.
• W2013994792 cites W2139540775 @default.
• W2013994792 cites W2143755247 @default.
• W2013994792 cites W2145486327 @default.
• W2013994792 cites W2145842062 @default.
• W2013994792 cites W2147934034 @default.
• W2013994792 cites W2157688021 @default.
• W2013994792 cites W2160697532 @default.
• W2013994792 cites W2165207521 @default.
• W2013994792 cites W238668910 @default.
• W2013994792 cites W307794556 @default.
• W2013994792 cites W349121293 @default.
• W2013994792 cites W4232414730 @default.
• W2013994792 cites W4232761037 @default.
• W2013994792 cites W4246992469 @default.
• W2013994792 doi "https://doi.org/10.1371/journal.pmed.0050083" @default.
• W2013994792 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2292747" @default.
• W2013994792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18416598" @default.
• W2013994792 hasPublicationYear "2008" @default.
• W2013994792 type Work @default.
• W2013994792 sameAs 2013994792 @default.
• W2013994792 citedByCount "70" @default.
• W2013994792 countsByYear W20139947922012 @default.
• W2013994792 countsByYear W20139947922013 @default.
• W2013994792 countsByYear W20139947922014 @default.
• W2013994792 countsByYear W20139947922015 @default.
• W2013994792 countsByYear W20139947922016 @default.
• W2013994792 countsByYear W20139947922017 @default.
• W2013994792 countsByYear W20139947922018 @default.
• W2013994792 countsByYear W20139947922019 @default.
• W2013994792 countsByYear W20139947922020 @default.
• W2013994792 countsByYear W20139947922021 @default.
• W2013994792 countsByYear W20139947922022 @default.
• W2013994792 countsByYear W20139947922023 @default.
• W2013994792 crossrefType "journal-article" @default.
• W2013994792 hasAuthorship W2013994792A5000373034 @default.
• W2013994792 hasAuthorship W2013994792A5006129290 @default.
• W2013994792 hasAuthorship W2013994792A5009866488 @default.
• W2013994792 hasAuthorship W2013994792A5018363328 @default.
• W2013994792 hasAuthorship W2013994792A5020088480 @default.
• W2013994792 hasAuthorship W2013994792A5022483928 @default.
• W2013994792 hasAuthorship W2013994792A5034189317 @default.
• W2013994792 hasAuthorship W2013994792A5035759509 @default.
• W2013994792 hasAuthorship W2013994792A5039997334 @default.
• W2013994792 hasAuthorship W2013994792A5049579176 @default.
• W2013994792 hasAuthorship W2013994792A5067594062 @default.
• W2013994792 hasAuthorship W2013994792A5077339582 @default.
• W2013994792 hasBestOaLocation W20139947921 @default.
• W2013994792 hasConcept C114851261 @default.
• W2013994792 hasConcept C121608353 @default.
• W2013994792 hasConcept C126322002 @default.
• W2013994792 hasConcept C143998085 @default.
• W2013994792 hasConcept C203014093 @default.
• W2013994792 hasConcept C207001950 @default.
• W2013994792 hasConcept C26291073 @default.

• next